View Financial HealthHolaluz-Clidom 配当と自社株買い配当金 基準チェック /06Holaluz-Clidom配当金を支払った記録がありません。主要情報n/a配当利回り-24.0%バイバック利回り総株主利回り-24.0%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesNew Risk • May 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Negative equity (-€28m). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€12m net loss in 2 years). Share price has been volatile over the past 3 months (6.4% average weekly change). Shareholders have been diluted in the past year (29% increase in shares outstanding). Market cap is less than US$100m (€26.9m market cap, or US$31.2m).お知らせ • Apr 24Holaluz-Clidom, S.A. to Report Fiscal Year 2025 Results on Apr 27, 2026Holaluz-Clidom, S.A. announced that they will report fiscal year 2025 results at 9:00 AM, Romance Standard Time on Apr 27, 2026New Risk • Jan 05New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€17m). Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (€9.1m net loss in 3 years). Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (€23.9m market cap, or US$28.0m).New Risk • Dec 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Spanish stocks, typically moving 6.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (6.5% average weekly change). Negative equity (-€17m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (€9.1m net loss in 3 years). Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (€19.3m market cap, or US$22.6m).New Risk • Dec 02New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: €31m Forecast net loss in 3 years: €9.1m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Negative equity (-€17m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (€9.1m net loss in 3 years). Share price has been volatile over the past 3 months (6.1% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (€21.8m market cap, or US$25.4m).New Risk • Nov 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Negative equity (-€17m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Share price has been volatile over the past 3 months (5.1% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (€24.6m market cap, or US$28.6m).お知らせ • Oct 28Holaluz-Clidom, S.A. to Report First Half, 2025 Results on Oct 30, 2025Holaluz-Clidom, S.A. announced that they will report first half, 2025 results on Oct 30, 2025お知らせ • May 23Holaluz-Clidom, S.A., Annual General Meeting, Jun 26, 2025Holaluz-Clidom, S.A., Annual General Meeting, Jun 26, 2025.New Risk • May 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.8% average weekly change). Negative equity (-€17m). Earnings have declined by 47% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (€29.5m market cap, or US$33.2m).New Risk • Nov 08New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€3.2m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-€3.2m). Earnings have declined by 55% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€30.2m market cap, or US$32.6m).お知らせ • Nov 06Holaluz-Clidom, S.A. announced that it expects to receive €22 million in funding from ICOSIUM Investment, S.LHolaluz-Clidom, S.A. announced a private placement to issue 3,600,000 common shares at an issue price of €1.80 per share for the gross proceeds of €6,840,000 and the second phase of the investment of the remaining €15,520,000, is expected to be completed within the following months at €2.10 per share through the subscription of a convertible loan. on November 4, 2024. The transaction will include participation from returning investor ICOSIUM Investment, S.L. with 14.12% stake. The initial phase will be the investment of €6,48,000 of capital contribution through the issuance of new common shares at €1.80 per share without pre-emptive rights, using the prior authorization granted by the This will grant ICOSIUM with 14,12% ownership of the Company. The investor will appoint one additional member to the Board of Directors of company. The total investment is €22,000,000 in the transaction.分析記事 • Jun 01Take Care Before Jumping Onto Holaluz-Clidom, S.A. (BME:HLZ) Even Though It's 46% CheaperThe Holaluz-Clidom, S.A. ( BME:HLZ ) share price has fared very poorly over the last month, falling by a substantial...Reported Earnings • May 05Full year 2023 earnings releasedFull year 2023 results: Revenue: €283.1m (down 69% from FY 2022). Net loss: €26.2m (loss widened 412% from FY 2022).New Risk • May 03New major risk - Revenue and earnings growthEarnings have declined by 80% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 80% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€56.1m market cap, or US$60.2m).お知らせ • Apr 26Holaluz-Clidom, S.A. to Report Fiscal Year 2023 Results on Apr 30, 2024Holaluz-Clidom, S.A. announced that they will report fiscal year 2023 results at 9:00 AM, Romance Standard Time on Apr 30, 2024Buy Or Sell Opportunity • Apr 24Now 27% undervalued after recent price dropOver the last 90 days, the stock has fallen 13% to €2.66. The fair value is estimated to be €3.63, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 43% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 20% in a year. Earnings are forecast to grow by 88% in the next year.お知らせ • Apr 23Holaluz-Clidom, S.A. announced that it expects to receive €8 million in fundingHolaluz-Clidom, S.A. announced a private placement of €2 million on convertible loan and €6 million equity line on April 23, 2024. The transaction will include participation from several Catalan family offices for convertible loan.分析記事 • Apr 16Holaluz-Clidom, S.A.'s (BME:HLZ) Share Price Boosted 28% But Its Business Prospects Need A Lift TooHolaluz-Clidom, S.A. ( BME:HLZ ) shareholders would be excited to see that the share price has had a great month...分析記事 • Apr 10Calculating The Intrinsic Value Of Holaluz-Clidom, S.A. (BME:HLZ)Key Insights Using the 2 Stage Free Cash Flow to Equity, Holaluz-Clidom fair value estimate is €3.63 With €3.17 share...Buy Or Sell Opportunity • Feb 08Now 22% undervaluedOver the last 90 days, the stock has risen 4.8% to €2.82. The fair value is estimated to be €3.63, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 43% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 20% in a year. Earnings are forecast to grow by 88% in the next year.分析記事 • Dec 29There's No Escaping Holaluz-Clidom, S.A.'s (BME:HLZ) Muted Revenues Despite A 42% Share Price RiseHolaluz-Clidom, S.A. ( BME:HLZ ) shareholders are no doubt pleased to see that the share price has bounced 42% in the...分析記事 • Dec 19Holaluz-Clidom, S.A.'s (BME:HLZ) Intrinsic Value Is Potentially 19% Below Its Share PriceKey Insights Holaluz-Clidom's estimated fair value is €3.41 based on 2 Stage Free Cash Flow to Equity Holaluz-Clidom is...Buying Opportunity • Nov 09Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 47%. The fair value is estimated to be €3.41, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 43% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 18% in a year. Earnings is forecast to grow by 79% in the next year.Reported Earnings • Nov 06First half 2023 earnings releasedFirst half 2023 results: €0.96 loss per share. Net loss: €20.9m (flat on 1H 2022). Revenue is expected to decline by 13% p.a. on average during the next 4 years, while revenues in the Electric Utilities industry in Spain are expected to grow by 1.5%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 37 percentage points per year, which is a significant difference in performance.分析記事 • Nov 03Holaluz-Clidom (BME:HLZ) Has Debt But No Earnings; Should You Worry?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...New Risk • Nov 01New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €5.1m Forecast net loss in 2 years: €3.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.6% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€3.4m net loss in 2 years). Market cap is less than US$100m (€72.0m market cap, or US$75.9m).Price Target Changed • Nov 01Price target decreased by 20% to €7.50Down from €9.35, the current price target is an average from 2 analysts. New target price is 130% above last closing price of €3.26. Stock is down 59% over the past year. The company posted a net loss per share of €0.23 last year.お知らせ • Oct 20Holaluz-Clidom, S.A. to Report First Half, 2023 Results on Oct 31, 2023Holaluz-Clidom, S.A. announced that they will report first half, 2023 results on Oct 31, 2023New Risk • Oct 11New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €89.5m (US$94.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (6.5% average weekly change). Minor Risk Market cap is less than US$100m (€89.5m market cap, or US$94.9m).分析記事 • Aug 25There Is A Reason Holaluz-Clidom, S.A.'s (BME:HLZ) Price Is UndemandingHolaluz-Clidom, S.A.'s ( BME:HLZ ) price-to-sales (or "P/S") ratio of 0.1x may look like a pretty appealing investment...New Risk • Jul 06New major risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Reported Earnings • May 03Full year 2022 earnings releasedFull year 2022 results: Revenue: €919.8m (up 61% from FY 2021). Net loss: €5.12m (loss narrowed 39% from FY 2021). Revenue is forecast to decline by 16% p.a. on average during the next 3 years, while revenues in the Electric Utilities industry in Spain are expected to remain flat.Price Target Changed • Apr 30Price target decreased by 15% to €11.50Down from €13.50, the current price target is an average from 2 analysts. New target price is 93% above last closing price of €5.96. Stock is down 53% over the past year. The company is forecast to post earnings per share of €0.31 next year compared to a net loss per share of €0.39 last year.Price Target Changed • Nov 16Price target decreased to €13.50Down from €14.65, the current price target is an average from 2 analysts. New target price is 69% above last closing price of €8.00. Stock is down 34% over the past year. The company posted a net loss per share of €0.39 last year.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). Independent Director Isabela Perez Nivela was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Price Target Changed • Oct 15Price target decreased to €13.50Down from €14.65, the current price target is an average from 2 analysts. New target price is 57% above last closing price of €8.60. Stock is down 28% over the past year. The company posted a net loss per share of €0.39 last year.Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). Independent Director Isabela Perez Nivela was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.分析記事 • Nov 28Holaluz-Clidom (BME:HLZ) Could Be Struggling To Allocate CapitalIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...分析記事 • May 31We Think Holaluz-Clidom (BME:HLZ) Is Taking Some Risk With Its DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Mar 10Do Institutions Own Holaluz-Clidom, S.A. (BME:HLZ) Shares?A look at the shareholders of Holaluz-Clidom, S.A. ( BME:HLZ ) can tell us which group is most powerful. Institutions...Is New 90 Day High Low • Feb 18New 90-day high: €9.40The company is up 30% from its price of €7.24 on 19 November 2020. The Spanish market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Electric Utilities industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.40 per share.Price Target Changed • Feb 11Price target raised to €13.05Up from €11.25, the current price target is an average from 2 analysts. The new target price is 49% above the current share price of €8.76. As of last close, the stock is down 4.8% over the past year.Is New 90 Day High Low • Dec 30New 90-day high: €7.96The company is up 17% from its price of €6.78 on 01 October 2020. The Spanish market is up 18% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Electric Utilities industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €6.14 per share.分析記事 • Nov 30Is Holaluz-Clidom, S.A. (BME:HLZ) Popular Amongst Insiders?If you want to know who really controls Holaluz-Clidom, S.A. (BME:HLZ), then you'll have to look at the makeup of its...Is New 90 Day High Low • Oct 06New 90-day high: €7.40The company is up 10.0% from its price of €6.75 on 08 July 2020. The Spanish market is down 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Electric Utilities industry, which is down 1.0% over the same period.決済の安定と成長配当データの取得安定した配当: HLZの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: HLZの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Holaluz-Clidom 配当利回り対市場HLZ 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (HLZ)n/a市場下位25% (ES)1.8%市場トップ25% (ES)5.4%業界平均 (Electric Utilities)3.7%アナリスト予想 (HLZ) (最長3年)n/a注目すべき配当: HLZは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: HLZは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: HLZの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: HLZが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YES 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 05:50終値2026/05/21 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Holaluz-Clidom, S.A. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Victor Peiro PérezGVC Gaesco ValoresPablo RiveraLighthouse-IEAF Servicios de Analisis
New Risk • May 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Negative equity (-€28m). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€12m net loss in 2 years). Share price has been volatile over the past 3 months (6.4% average weekly change). Shareholders have been diluted in the past year (29% increase in shares outstanding). Market cap is less than US$100m (€26.9m market cap, or US$31.2m).
お知らせ • Apr 24Holaluz-Clidom, S.A. to Report Fiscal Year 2025 Results on Apr 27, 2026Holaluz-Clidom, S.A. announced that they will report fiscal year 2025 results at 9:00 AM, Romance Standard Time on Apr 27, 2026
New Risk • Jan 05New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€17m). Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (€9.1m net loss in 3 years). Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (€23.9m market cap, or US$28.0m).
New Risk • Dec 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Spanish stocks, typically moving 6.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (6.5% average weekly change). Negative equity (-€17m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (€9.1m net loss in 3 years). Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (€19.3m market cap, or US$22.6m).
New Risk • Dec 02New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: €31m Forecast net loss in 3 years: €9.1m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Negative equity (-€17m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (€9.1m net loss in 3 years). Share price has been volatile over the past 3 months (6.1% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (€21.8m market cap, or US$25.4m).
New Risk • Nov 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Negative equity (-€17m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Share price has been volatile over the past 3 months (5.1% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (€24.6m market cap, or US$28.6m).
お知らせ • Oct 28Holaluz-Clidom, S.A. to Report First Half, 2025 Results on Oct 30, 2025Holaluz-Clidom, S.A. announced that they will report first half, 2025 results on Oct 30, 2025
お知らせ • May 23Holaluz-Clidom, S.A., Annual General Meeting, Jun 26, 2025Holaluz-Clidom, S.A., Annual General Meeting, Jun 26, 2025.
New Risk • May 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.8% average weekly change). Negative equity (-€17m). Earnings have declined by 47% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (€29.5m market cap, or US$33.2m).
New Risk • Nov 08New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€3.2m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-€3.2m). Earnings have declined by 55% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€30.2m market cap, or US$32.6m).
お知らせ • Nov 06Holaluz-Clidom, S.A. announced that it expects to receive €22 million in funding from ICOSIUM Investment, S.LHolaluz-Clidom, S.A. announced a private placement to issue 3,600,000 common shares at an issue price of €1.80 per share for the gross proceeds of €6,840,000 and the second phase of the investment of the remaining €15,520,000, is expected to be completed within the following months at €2.10 per share through the subscription of a convertible loan. on November 4, 2024. The transaction will include participation from returning investor ICOSIUM Investment, S.L. with 14.12% stake. The initial phase will be the investment of €6,48,000 of capital contribution through the issuance of new common shares at €1.80 per share without pre-emptive rights, using the prior authorization granted by the This will grant ICOSIUM with 14,12% ownership of the Company. The investor will appoint one additional member to the Board of Directors of company. The total investment is €22,000,000 in the transaction.
分析記事 • Jun 01Take Care Before Jumping Onto Holaluz-Clidom, S.A. (BME:HLZ) Even Though It's 46% CheaperThe Holaluz-Clidom, S.A. ( BME:HLZ ) share price has fared very poorly over the last month, falling by a substantial...
Reported Earnings • May 05Full year 2023 earnings releasedFull year 2023 results: Revenue: €283.1m (down 69% from FY 2022). Net loss: €26.2m (loss widened 412% from FY 2022).
New Risk • May 03New major risk - Revenue and earnings growthEarnings have declined by 80% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 80% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€56.1m market cap, or US$60.2m).
お知らせ • Apr 26Holaluz-Clidom, S.A. to Report Fiscal Year 2023 Results on Apr 30, 2024Holaluz-Clidom, S.A. announced that they will report fiscal year 2023 results at 9:00 AM, Romance Standard Time on Apr 30, 2024
Buy Or Sell Opportunity • Apr 24Now 27% undervalued after recent price dropOver the last 90 days, the stock has fallen 13% to €2.66. The fair value is estimated to be €3.63, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 43% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 20% in a year. Earnings are forecast to grow by 88% in the next year.
お知らせ • Apr 23Holaluz-Clidom, S.A. announced that it expects to receive €8 million in fundingHolaluz-Clidom, S.A. announced a private placement of €2 million on convertible loan and €6 million equity line on April 23, 2024. The transaction will include participation from several Catalan family offices for convertible loan.
分析記事 • Apr 16Holaluz-Clidom, S.A.'s (BME:HLZ) Share Price Boosted 28% But Its Business Prospects Need A Lift TooHolaluz-Clidom, S.A. ( BME:HLZ ) shareholders would be excited to see that the share price has had a great month...
分析記事 • Apr 10Calculating The Intrinsic Value Of Holaluz-Clidom, S.A. (BME:HLZ)Key Insights Using the 2 Stage Free Cash Flow to Equity, Holaluz-Clidom fair value estimate is €3.63 With €3.17 share...
Buy Or Sell Opportunity • Feb 08Now 22% undervaluedOver the last 90 days, the stock has risen 4.8% to €2.82. The fair value is estimated to be €3.63, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 43% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 20% in a year. Earnings are forecast to grow by 88% in the next year.
分析記事 • Dec 29There's No Escaping Holaluz-Clidom, S.A.'s (BME:HLZ) Muted Revenues Despite A 42% Share Price RiseHolaluz-Clidom, S.A. ( BME:HLZ ) shareholders are no doubt pleased to see that the share price has bounced 42% in the...
分析記事 • Dec 19Holaluz-Clidom, S.A.'s (BME:HLZ) Intrinsic Value Is Potentially 19% Below Its Share PriceKey Insights Holaluz-Clidom's estimated fair value is €3.41 based on 2 Stage Free Cash Flow to Equity Holaluz-Clidom is...
Buying Opportunity • Nov 09Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 47%. The fair value is estimated to be €3.41, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 43% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 18% in a year. Earnings is forecast to grow by 79% in the next year.
Reported Earnings • Nov 06First half 2023 earnings releasedFirst half 2023 results: €0.96 loss per share. Net loss: €20.9m (flat on 1H 2022). Revenue is expected to decline by 13% p.a. on average during the next 4 years, while revenues in the Electric Utilities industry in Spain are expected to grow by 1.5%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 37 percentage points per year, which is a significant difference in performance.
分析記事 • Nov 03Holaluz-Clidom (BME:HLZ) Has Debt But No Earnings; Should You Worry?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Risk • Nov 01New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €5.1m Forecast net loss in 2 years: €3.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.6% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€3.4m net loss in 2 years). Market cap is less than US$100m (€72.0m market cap, or US$75.9m).
Price Target Changed • Nov 01Price target decreased by 20% to €7.50Down from €9.35, the current price target is an average from 2 analysts. New target price is 130% above last closing price of €3.26. Stock is down 59% over the past year. The company posted a net loss per share of €0.23 last year.
お知らせ • Oct 20Holaluz-Clidom, S.A. to Report First Half, 2023 Results on Oct 31, 2023Holaluz-Clidom, S.A. announced that they will report first half, 2023 results on Oct 31, 2023
New Risk • Oct 11New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €89.5m (US$94.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (6.5% average weekly change). Minor Risk Market cap is less than US$100m (€89.5m market cap, or US$94.9m).
分析記事 • Aug 25There Is A Reason Holaluz-Clidom, S.A.'s (BME:HLZ) Price Is UndemandingHolaluz-Clidom, S.A.'s ( BME:HLZ ) price-to-sales (or "P/S") ratio of 0.1x may look like a pretty appealing investment...
New Risk • Jul 06New major risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Reported Earnings • May 03Full year 2022 earnings releasedFull year 2022 results: Revenue: €919.8m (up 61% from FY 2021). Net loss: €5.12m (loss narrowed 39% from FY 2021). Revenue is forecast to decline by 16% p.a. on average during the next 3 years, while revenues in the Electric Utilities industry in Spain are expected to remain flat.
Price Target Changed • Apr 30Price target decreased by 15% to €11.50Down from €13.50, the current price target is an average from 2 analysts. New target price is 93% above last closing price of €5.96. Stock is down 53% over the past year. The company is forecast to post earnings per share of €0.31 next year compared to a net loss per share of €0.39 last year.
Price Target Changed • Nov 16Price target decreased to €13.50Down from €14.65, the current price target is an average from 2 analysts. New target price is 69% above last closing price of €8.00. Stock is down 34% over the past year. The company posted a net loss per share of €0.39 last year.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). Independent Director Isabela Perez Nivela was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Price Target Changed • Oct 15Price target decreased to €13.50Down from €14.65, the current price target is an average from 2 analysts. New target price is 57% above last closing price of €8.60. Stock is down 28% over the past year. The company posted a net loss per share of €0.39 last year.
Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). Independent Director Isabela Perez Nivela was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
分析記事 • Nov 28Holaluz-Clidom (BME:HLZ) Could Be Struggling To Allocate CapitalIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
分析記事 • May 31We Think Holaluz-Clidom (BME:HLZ) Is Taking Some Risk With Its DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Mar 10Do Institutions Own Holaluz-Clidom, S.A. (BME:HLZ) Shares?A look at the shareholders of Holaluz-Clidom, S.A. ( BME:HLZ ) can tell us which group is most powerful. Institutions...
Is New 90 Day High Low • Feb 18New 90-day high: €9.40The company is up 30% from its price of €7.24 on 19 November 2020. The Spanish market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Electric Utilities industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.40 per share.
Price Target Changed • Feb 11Price target raised to €13.05Up from €11.25, the current price target is an average from 2 analysts. The new target price is 49% above the current share price of €8.76. As of last close, the stock is down 4.8% over the past year.
Is New 90 Day High Low • Dec 30New 90-day high: €7.96The company is up 17% from its price of €6.78 on 01 October 2020. The Spanish market is up 18% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Electric Utilities industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €6.14 per share.
分析記事 • Nov 30Is Holaluz-Clidom, S.A. (BME:HLZ) Popular Amongst Insiders?If you want to know who really controls Holaluz-Clidom, S.A. (BME:HLZ), then you'll have to look at the makeup of its...
Is New 90 Day High Low • Oct 06New 90-day high: €7.40The company is up 10.0% from its price of €6.75 on 08 July 2020. The Spanish market is down 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Electric Utilities industry, which is down 1.0% over the same period.